S&P 500   3,319.47 (-1.12%)
DOW   27,657.42 (-0.88%)
QQQ   266.87 (-1.28%)
AAPL   106.84 (-3.17%)
MSFT   200.39 (-1.24%)
FB   252.53 (-0.90%)
GOOGL   1,451.09 (-2.42%)
AMZN   2,954.91 (-1.79%)
NVDA   487.57 (-2.20%)
TSLA   442.15 (+4.42%)
BABA   272.41 (-1.20%)
CGC   16.36 (-0.24%)
GE   6.88 (-2.41%)
MU   50.74 (-0.47%)
AMD   74.93 (-2.12%)
T   28.93 (-0.48%)
F   7.23 (-0.69%)
ACB   6.53 (-5.22%)
GILD   65.05 (+0.02%)
NFLX   469.96 (-0.05%)
DIS   128.63 (-1.22%)
BAC   25.21 (-0.55%)
BA   161.14 (-3.81%)
S&P 500   3,319.47 (-1.12%)
DOW   27,657.42 (-0.88%)
QQQ   266.87 (-1.28%)
AAPL   106.84 (-3.17%)
MSFT   200.39 (-1.24%)
FB   252.53 (-0.90%)
GOOGL   1,451.09 (-2.42%)
AMZN   2,954.91 (-1.79%)
NVDA   487.57 (-2.20%)
TSLA   442.15 (+4.42%)
BABA   272.41 (-1.20%)
CGC   16.36 (-0.24%)
GE   6.88 (-2.41%)
MU   50.74 (-0.47%)
AMD   74.93 (-2.12%)
T   28.93 (-0.48%)
F   7.23 (-0.69%)
ACB   6.53 (-5.22%)
GILD   65.05 (+0.02%)
NFLX   469.96 (-0.05%)
DIS   128.63 (-1.22%)
BAC   25.21 (-0.55%)
BA   161.14 (-3.81%)
S&P 500   3,319.47 (-1.12%)
DOW   27,657.42 (-0.88%)
QQQ   266.87 (-1.28%)
AAPL   106.84 (-3.17%)
MSFT   200.39 (-1.24%)
FB   252.53 (-0.90%)
GOOGL   1,451.09 (-2.42%)
AMZN   2,954.91 (-1.79%)
NVDA   487.57 (-2.20%)
TSLA   442.15 (+4.42%)
BABA   272.41 (-1.20%)
CGC   16.36 (-0.24%)
GE   6.88 (-2.41%)
MU   50.74 (-0.47%)
AMD   74.93 (-2.12%)
T   28.93 (-0.48%)
F   7.23 (-0.69%)
ACB   6.53 (-5.22%)
GILD   65.05 (+0.02%)
NFLX   469.96 (-0.05%)
DIS   128.63 (-1.22%)
BAC   25.21 (-0.55%)
BA   161.14 (-3.81%)
S&P 500   3,319.47 (-1.12%)
DOW   27,657.42 (-0.88%)
QQQ   266.87 (-1.28%)
AAPL   106.84 (-3.17%)
MSFT   200.39 (-1.24%)
FB   252.53 (-0.90%)
GOOGL   1,451.09 (-2.42%)
AMZN   2,954.91 (-1.79%)
NVDA   487.57 (-2.20%)
TSLA   442.15 (+4.42%)
BABA   272.41 (-1.20%)
CGC   16.36 (-0.24%)
GE   6.88 (-2.41%)
MU   50.74 (-0.47%)
AMD   74.93 (-2.12%)
T   28.93 (-0.48%)
F   7.23 (-0.69%)
ACB   6.53 (-5.22%)
GILD   65.05 (+0.02%)
NFLX   469.96 (-0.05%)
DIS   128.63 (-1.22%)
BAC   25.21 (-0.55%)
BA   161.14 (-3.81%)
Log in
NASDAQ:CBIO

Catalyst Biosciences Stock Forecast, Price & News

$4.82
-0.02 (-0.41 %)
(As of 09/18/2020 12:00 AM ET)
Add
Compare
Today's Range
$4.74
Now: $4.82
$5.21
50-Day Range
$4.55
MA: $5.09
$5.66
52-Week Range
$3.43
Now: $4.82
$8.94
Volume584,274 shs
Average Volume280,226 shs
Market Capitalization$106.34 million
P/E RatioN/A
Dividend YieldN/A
Beta2.19
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors. The company is also developing Dalcinonacog alfa, a Factor IX drug, which has completed enrollment of a Phase I/II subcutaneous dosing trial for the prophylactic treatment of individuals with hemophilia B; CB 2679d-GT, a FIX gene therapy for the treatment of hemophilia B; and CB 2782, an anti-C3 protease program for the treatment of dry age-related macular degeneration (AMD), as well as CB 1965a, a Factor Xa therapeutic program used as a universal procoagulant. Catalyst Biosciences, Inc. has collaboration agreement with Pfizer, Inc. for the development of human Factor VIIa products; and ISU Abxis. The company has strategic research collaboration with Mosaic Biosciences, Inc. to develop intravitreal anti-complement factor 3 products for the treatment of dry AMD and other retinal diseases. The company was founded in 2002 and is headquartered in South San Francisco, California.
Read More
Catalyst Biosciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.55 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:CBIO
CUSIP87611R30
Phone650-871-0761

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10,000.00
Price / Sales10,634.37
Book Value$5.68 per share

Profitability

Net Income$-55,180,000.00

Miscellaneous

Employees21
Market Cap$106.34 million
Next Earnings Date11/5/2020 (Estimated)
OptionableOptionable
$4.82
-0.02 (-0.41 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for CBIO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Catalyst Biosciences (NASDAQ:CBIO) Frequently Asked Questions

How has Catalyst Biosciences' stock price been impacted by Coronavirus?

Catalyst Biosciences' stock was trading at $4.83 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CBIO stock has decreased by 0.2% and is now trading at $4.82.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Catalyst Biosciences?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalyst Biosciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Catalyst Biosciences
.

When is Catalyst Biosciences' next earnings date?

Catalyst Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Catalyst Biosciences
.

How were Catalyst Biosciences' earnings last quarter?

Catalyst Biosciences Inc (NASDAQ:CBIO) posted its quarterly earnings results on Thursday, August, 6th. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.86) by $0.10. The biopharmaceutical company earned $1.66 million during the quarter.
View Catalyst Biosciences' earnings history
.

When did Catalyst Biosciences' stock split? How did Catalyst Biosciences' stock split work?

Shares of Catalyst Biosciences reverse split before market open on Monday, February 13th 2017. The 1-15 reverse split was announced on Friday, February 10th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 10th 2017. An investor that had 100 shares of Catalyst Biosciences stock prior to the reverse split would have 7 shares after the split.

What price target have analysts set for CBIO?

3 analysts have issued twelve-month price objectives for Catalyst Biosciences' stock. Their forecasts range from $18.00 to $25.00. On average, they expect Catalyst Biosciences' share price to reach $21.00 in the next year. This suggests a possible upside of 335.7% from the stock's current price.
View analysts' price targets for Catalyst Biosciences
.

Who are some of Catalyst Biosciences' key competitors?

What other stocks do shareholders of Catalyst Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Biosciences investors own include Baozun (BZUN), Inovio Pharmaceuticals (INO), Amarin (AMRN), Celsion (CLSN), Sangamo Therapeutics (SGMO), Sarepta Therapeutics (SRPT), Catalyst Pharmaceuticals (CPRX), ImmunoGen (IMGN), Nabriva Therapeutics (NBRV) and Biocept (BIOC).

Who are Catalyst Biosciences' key executives?

Catalyst Biosciences' management team includes the following people:
  • Dr. Nassim Usman, Pres, CEO & Director (Age 59)
  • Mr. Fletcher Payne, Chief Financial Officer (Age 56)
  • Dr. Howard Levy, Chief Medical Officer (Age 65)
  • Dr. Charles S. Craik, Co-Founder & Chairman of Scientific Advisory Board
  • Mr. Andrew Hetherington M.B.A., Sr. VP of Technical Operations

What is Catalyst Biosciences' stock symbol?

Catalyst Biosciences trades on the NASDAQ under the ticker symbol "CBIO."

Who are Catalyst Biosciences' major shareholders?

Catalyst Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include Nantahala Capital Management LLC (15.08%), Two Sigma Advisers LP (1.31%), Prosight Management LP (2.05%), Alyeska Investment Group L.P. (1.81%), UBS Group AG (1.33%) and Assenagon Asset Management S.A. (1.25%). Company insiders that own Catalyst Biosciences stock include Eddie Williams, Howard Levy, John P Richard, Nassim Usman and Veronica Cai.
View institutional ownership trends for Catalyst Biosciences
.

Which major investors are selling Catalyst Biosciences stock?

CBIO stock was sold by a variety of institutional investors in the last quarter, including Prosight Management LP, Bank of America Corp DE, Marquette Asset Management LLC, and PDT Partners LLC.
View insider buying and selling activity for Catalyst Biosciences
.

Which major investors are buying Catalyst Biosciences stock?

CBIO stock was bought by a variety of institutional investors in the last quarter, including Nantahala Capital Management LLC, Alyeska Investment Group L.P., UBS Group AG, Assenagon Asset Management S.A., M Holdings Securities Inc., Jacobs Levy Equity Management Inc., Two Sigma Advisers LP, and Schonfeld Strategic Advisors LLC. Company insiders that have bought Catalyst Biosciences stock in the last two years include Eddie Williams, Howard Levy, John P Richard, Nassim Usman, and Veronica Cai.
View insider buying and selling activity for Catalyst Biosciences
.

How do I buy shares of Catalyst Biosciences?

Shares of CBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Catalyst Biosciences' stock price today?

One share of CBIO stock can currently be purchased for approximately $4.82.

How big of a company is Catalyst Biosciences?

Catalyst Biosciences has a market capitalization of $106.34 million and generates $10,000.00 in revenue each year. The biopharmaceutical company earns $-55,180,000.00 in net income (profit) each year or ($4.60) on an earnings per share basis. Catalyst Biosciences employs 21 workers across the globe.

What is Catalyst Biosciences' official website?

The official website for Catalyst Biosciences is www.catalystbiosciences.com.

How can I contact Catalyst Biosciences?

Catalyst Biosciences' mailing address is 611 GATEWAY BLVD. SUITE 710, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-871-0761 or via email at [email protected]

This page was last updated on 9/18/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.